Optinose Reports Second Quarter 2024 Financial Results and Recent Operational Highlights
August 08, 2024 07:00 ET
|
Optinose, Inc.
Company reports Q2 2024 XHANCE net revenue of $20.5 million, an increase of 5% compared to Q2 2023 XHANCE has been added to Express Scripts’ national formularies, among the largest commercial...
Optinose Announces Reporting Date for Second Quarter 2024 Financial Results
August 02, 2024 08:30 ET
|
Optinose, Inc.
YARDLEY, Pa., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Expanded Access to XHANCE with Addition to National Commercial Formularies
June 27, 2024 07:00 ET
|
Optinose, Inc.
YARDLEY, Pa., June 27, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
May 17, 2024 12:00 ET
|
Optinose, Inc.
YARDLEY, Pa., May 17, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Announces Reporting Date for First Quarter 2024 Financial Results
May 10, 2024 14:56 ET
|
Optinose, Inc.
YARDLEY, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the...
Optinose Announces $55 Million Registered Direct Offering
May 09, 2024 07:00 ET
|
Optinose, Inc.
Led by Nantahala Capital and The D. E. Shaw Group with participation from existing and new investors Post-offering cash balance of ~$100 million expected to fund operating plan through 2025 ...
Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 million
April 25, 2024 07:00 ET
|
Optinose, Inc.
YARDLEY, Pa., April 25, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose to Present at the Needham Virtual Healthcare Conference
April 04, 2024 16:01 ET
|
Optinose, Inc.
YARDLEY, Pa., April 04, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps
March 15, 2024 15:34 ET
|
Optinose, Inc.
ReOpen was the first ever large placebo-controlled clinical trial program to demonstrate statistically significant reduction of symptoms in chronic sinusitis patients without nasal polyps Clinical...
Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
March 07, 2024 07:00 ET
|
Optinose, Inc.
PDUFA target action date is March 16, 2024, for the Company's sNDA. If approved, the Company is prepared for launch of XHANCE for treatment of patients diagnosed with chronic sinusitis Physicians...